上皮癌-话题@MedSci

#上皮癌#

151篇内容 | 3341人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1539385, encodeId=2d861539385bc, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=ESMO Open：抗PD-(L)1抗体治疗转移性尿路上皮癌的预后, objectType=article, longId=208783, objectId=b41c208e8335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41c208e8335, replyNumber=0, likeNumber=55, createdTime=2021-03-22, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41c208e8335, moduleTitle=ESMO Open：抗PD-(L)1抗体治疗转移性尿路上皮癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41c208e8335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539384, encodeId=2553153938493, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Lancet oncol：阿特朱单抗用作高风险的肌肉浸润性尿路上皮癌的术后辅助疗法的疗效, objectType=article, longId=208560, objectId=971f208560b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=971f208560b8, replyNumber=0, likeNumber=0, createdTime=2021-03-19, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=971f208560b8, moduleTitle=Lancet oncol：阿特朱单抗用作高风险的肌肉浸润性尿路上皮癌的术后辅助疗法的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=971f208560b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539383, encodeId=6bd0153938302, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=尿路上皮癌领域必读的2020年关键性研究论文, objectType=article, longId=207232, objectId=da0720e232ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da0720e232ae, replyNumber=0, likeNumber=76, createdTime=2021-02-19, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da0720e232ae, moduleTitle=尿路上皮癌领域必读的2020年关键性研究论文, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da0720e232ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539382, encodeId=6558153938207, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）, objectType=article, longId=207205, objectId=96bf20e20583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96bf20e20583, replyNumber=0, likeNumber=0, createdTime=2021-02-18, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96bf20e20583, moduleTitle=ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96bf20e20583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539381, encodeId=d0181539381fd, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=ASCO GU 2021: 阿替利珠单抗一线治疗局晚或转移的尿路上皮癌结果发布（IMvigor130研究）, objectType=article, longId=207204, objectId=d52d20e20494, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d52d20e20494, replyNumber=0, likeNumber=61, createdTime=2021-02-18, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d52d20e20494, moduleTitle=ASCO GU 2021: 阿替利珠单抗一线治疗局晚或转移的尿路上皮癌结果发布（IMvigor130研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d52d20e20494)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539380, encodeId=13af1539380fc, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=ASCO GU 2021：上尿路尿路上皮癌的术后辅助化疗III期POUT试验结果更新, objectType=article, longId=207175, objectId=d83c20e175d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d83c20e175d0, replyNumber=0, likeNumber=68, createdTime=2021-02-17, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d83c20e175d0, moduleTitle=ASCO GU 2021：上尿路尿路上皮癌的术后辅助化疗III期POUT试验结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d83c20e175d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539379, encodeId=a6d815393e9be, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=纳武利尤单抗用于根治手术后高复发风险肌层浸润性尿路上皮癌治疗取得成功（CheckMate -274研究）, objectType=article, longId=207160, objectId=c47f20e16003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c47f20e16003, replyNumber=0, likeNumber=72, createdTime=2021-02-17, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c47f20e16003, moduleTitle=纳武利尤单抗用于根治手术后高复发风险肌层浸润性尿路上皮癌治疗取得成功（CheckMate -274研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c47f20e16003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539378, encodeId=09cb15393e832, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用, objectType=article, longId=207094, objectId=a84a20e094e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a84a20e094e5, replyNumber=0, likeNumber=73, createdTime=2021-02-15, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a84a20e094e5, moduleTitle=NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a84a20e094e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539377, encodeId=664815393e7b9, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=欧狄沃辅助治疗肌层浸润性尿路上皮癌延长患者无病生存期近2倍, objectType=article, longId=206995, objectId=c74f20699566, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c74f20699566, replyNumber=0, likeNumber=89, createdTime=2021-02-10, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c74f20699566, moduleTitle=欧狄沃辅助治疗肌层浸润性尿路上皮癌延长患者无病生存期近2倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c74f20699566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539376, encodeId=338015393e6b8, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Br J Cancer：浆细胞样尿路上皮癌的系统疗法反应及基因表达状况, objectType=article, longId=206297, objectId=9b4c20629eda, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b4c20629eda, replyNumber=0, likeNumber=53, createdTime=2021-01-28, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b4c20629eda, moduleTitle=Br J Cancer：浆细胞样尿路上皮癌的系统疗法反应及基因表达状况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b4c20629eda)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539375, encodeId=7c5115393e577, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法, objectType=article, longId=202749, objectId=c7e3202e494d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7e3202e494d, replyNumber=0, likeNumber=29, createdTime=2020-11-03, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7e3202e494d, moduleTitle=Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7e3202e494d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539374, encodeId=297415393e4c8, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=NEJM：avelumab用于晚期尿路上皮癌患者化疗后的维持治疗, objectType=article, longId=201175, objectId=e4c42011e553, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c42011e553, replyNumber=0, likeNumber=74, createdTime=2020-09-26, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c42011e553, moduleTitle=NEJM：avelumab用于晚期尿路上皮癌患者化疗后的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4c42011e553)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539373, encodeId=72a115393e3e6, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle= Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌, objectType=article, longId=201131, objectId=a81a2011316b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a81a2011316b, replyNumber=0, likeNumber=109, createdTime=2020-09-25, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a81a2011316b, moduleTitle= Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a81a2011316b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539372, encodeId=d92c15393e208, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=荣昌生物纬迪西妥单抗（RC48）治疗尿路上皮癌获FDA突破性疗法认定, objectType=article, longId=201087, objectId=e72920108ee8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e72920108ee8, replyNumber=0, likeNumber=67, createdTime=2020-09-24, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e72920108ee8, moduleTitle=荣昌生物纬迪西妥单抗（RC48）治疗尿路上皮癌获FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e72920108ee8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539371, encodeId=079d15393e1ce, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=尿路上皮癌重磅研究荟萃：KEYNOTE-361、DANUBE、TROPHY-U-01, objectType=article, longId=201027, objectId=4d2c20102e70, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d2c20102e70, replyNumber=0, likeNumber=82, createdTime=2020-09-23, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d2c20102e70, moduleTitle=尿路上皮癌重磅研究荟萃：KEYNOTE-361、DANUBE、TROPHY-U-01, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d2c20102e70)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539370, encodeId=0a1515393e0d0, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=杨勇教授：替雷利珠单抗在尿路上皮癌一线免疫联合治疗展示曙光, objectType=article, longId=201006, objectId=cac3201006d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cac3201006d4, replyNumber=0, likeNumber=84, createdTime=2020-09-23, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cac3201006d4, moduleTitle=杨勇教授：替雷利珠单抗在尿路上皮癌一线免疫联合治疗展示曙光, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cac3201006d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539369, encodeId=f65d1539369aa, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Clini Cancer Res：纳武单抗治疗晚期铂耐药尿路上皮癌, objectType=article, longId=198081, objectId=67a5198081df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67a5198081df, replyNumber=0, likeNumber=69, createdTime=2020-07-28, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67a5198081df, moduleTitle=Clini Cancer Res：纳武单抗治疗晚期铂耐药尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67a5198081df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539368, encodeId=edf2153936804, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌, objectType=article, longId=197602, objectId=cbf019e602e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf019e602e0, replyNumber=0, likeNumber=54, createdTime=2020-07-17, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf019e602e0, moduleTitle=抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbf019e602e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539367, encodeId=5df5153936e6f, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=Lancet oncol：卡博替尼治疗铂耐药的转移性尿路上皮癌, objectType=article, longId=197427, objectId=6caa19e42798, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6caa19e42798, replyNumber=0, likeNumber=56, createdTime=2020-07-14, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6caa19e42798, moduleTitle=Lancet oncol：卡博替尼治疗铂耐药的转移性尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6caa19e42798)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539366, encodeId=5c5f153936682, content=<a href='/topic/show?id=0e802002e45' target=_blank style='color:#2F92EE;'>#上皮癌#</a>, objectTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, objectType=article, longId=196892, objectId=c2de19689221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2de19689221, replyNumber=0, likeNumber=50, createdTime=2020-07-03, rootId=0, userName=mashirong, userId=866a13134648, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2de19689221, moduleTitle=PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2de19689221)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

上皮癌

2020-05-29

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

ESMO Open：抗PD-(L)1抗体治疗转移性尿路上皮癌的预后

2021-03-22

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Lancet oncol：阿特朱单抗用作高风险的肌肉浸润性尿路上皮癌的术后辅助疗法的疗效

2021-03-19

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

尿路上皮癌领域必读的2020年关键性研究论文

2021-02-19

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）

2021-02-18

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

ASCO GU 2021: 阿替利珠单抗一线治疗局晚或转移的尿路上皮癌结果发布（IMvigor130研究）

2021-02-18

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

ASCO GU 2021：上尿路尿路上皮癌的术后辅助化疗III期POUT试验结果更新

2021-02-17

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

纳武利尤单抗用于根治手术后高复发风险肌层浸润性尿路上皮癌治疗取得成功（CheckMate -274研究）

2021-02-17

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用

2021-02-15

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

欧狄沃辅助治疗肌层浸润性尿路上皮癌延长患者无病生存期近2倍

2021-02-10

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Br J Cancer：浆细胞样尿路上皮癌的系统疗法反应及基因表达状况

2021-01-28

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Nat Med：不适合顺铂治疗的高风险尿路上皮癌患者的新辅助PD-L1加CTLA-4阻断疗法

2020-11-03

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

NEJM：avelumab用于晚期尿路上皮癌患者化疗后的维持治疗

2020-09-26

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Lancet oncol：PD-L1抑制剂Durvalumab±曲美单抗治疗转移性尿路上皮癌

2020-09-25

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

荣昌生物纬迪西妥单抗（RC48）治疗尿路上皮癌获FDA突破性疗法认定

2020-09-24

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

尿路上皮癌重磅研究荟萃：KEYNOTE-361、DANUBE、TROPHY-U-01

2020-09-23

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

杨勇教授：替雷利珠单抗在尿路上皮癌一线免疫联合治疗展示曙光

2020-09-23

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Clini Cancer Res：纳武单抗治疗晚期铂耐药尿路上皮癌

2020-07-28

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

抗Trop-2的ADC药物Trodelvy联合PD-L1单抗Tecentriq：治疗尿道上皮癌和非小细胞肺癌

2020-07-17

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

Lancet oncol：卡博替尼治疗铂耐药的转移性尿路上皮癌

2020-07-14

mashirong (审核中...)

前往app查看评论内容

#上皮癌#

PD-L1单抗Bavencio，获得FDA批准用于晚期或转移性尿路上皮癌患者的维持治疗

2020-07-03

科室
- - 订阅+
  - 更多科室
工具
服务